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RadiotherapyAim: In a pilot prospective study, we aimed to test the feasibility and report on the preliminary results on
the expression of molecular biomarkers in wound drainage fluids (WDFs) of operated head and neck
squamous cell carcinoma (HNSCC) patients.
Material and methods: Nineteen patients undergoing primary tumor resection with en-block neck
dissection were enrolled. In postoperative days 1–3, the expression of several biomarkers in WDFs was
measured using enzyme-linked immunosorbent assay (ELISA) kits and correlated with clinical and
histopathologic features.
Results: The expression of stromal cell-derived factor 1 (CXCL-12) was significantly increased in WDFs in
presence of lymph node metastases, extranodal extension (ENE), and in case of close resection margins. In
addition, Osteopontin expression was significantly increased in presence of ENE, whereas transforming
growth factor beta (TGF-b) detection was significantly reduced. At multivariate analysis, CXCL-2 levels
in both day 1 and 3 post-surgery were the only factor which retained significance in the prediction of
close surgical margins (p = 0.028 and 0.025 for day 1 and day 3, respectively). Both CXCL-2 and
Ostepontin assays were significantly correlated with ENE (p = 0.018 and 0.035 for day 1; 0.052 and
0.025 for day 3, respectively) whereas TGF- b expression was significant at day 1 only (p = 0.038)
Conclusions: Our pilot study showed that WDFs could qualify as a potential source of relevant postoper-
ative information. Further studies are needed to confirm the prognostic impact of CXCL-12, Osteopontin
and TGF-b expressed in WDFs on the personalized management of HNSCC.
 2020 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The incidence of head and neck squamous cell carcinoma
(HNSCC) is increasing: worldwide, it represents the sixth most
common neoplasm, affecting more than 550.000 patients per year
[1,2]. In over 60% of cases, HNSCC is diagnosed at a loco-regionally
advanced stage, requiring a multimodal strategy in order to pursue
a curative intent. In the post-operative setting the rationale of a
combined therapeutic approach, when an estimated risk of resid-
ual microscopic disease is present, is to minimize the risk of a
macroscopic recurrence. Indeed, HNSCC-related mortality is
mainly driven by a predominant loco-regional pattern of failure
[3]. It has long been known that the presence of lymph nodemetastases has the largest impact on prognosis, overall reducing
cancer-specific survival (CSS) by about 50% [4], with extranodal
extension (ENE) portending worse regional and distant metastatic
failure rates [5]. In the setting of primary surgery, the potential
causative role of manipulations during intervention in facilitating
loco-regional seeding of viable tumor cells has never been fully
elucidated, nor is the hypothetical impact of growth factors
involved in wound healing in stimulating the proliferative capacity
of HNSCC clonogens [6,7]. With the notable exception of Human
Papilloma Virus (HPV) infection for oropharyngeal cancer, no
molecular biomarkers are currently available in the clinic to tailor
the choice of treatment at an individual level. In recent years, the
biologic interplay of the tumor microenvironment in respect to
hypoxia, inflammation and neo-angiogenesis was actively investi-
gated [8]. Interest was drawn to assess the presence of growth fac-
tors in wound drainage fluids (WDFs) secreted by the host during
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damage that may boost residual tumor cells proliferation [9].
Among them, high levels of Epidermal Growth Factor Receptor
(EGFR) protein and of its ligand were shown to be prognosticators
of reduced disease-free survival (DFS) and CSS [10]. However, these
findings were not corroborated by further evidence to support
their post-operative assessment in clinical decision-making. Based
on the hypothesis that WDFs obtained by neck dissection drain
tubes could reliably provide information on the tumor microenvi-
roment, we designed a pilot feasibility study aiming to determine
the presence and potential prognostic relevance of the following
soluble protein biomarkers: Epidermal Growth Factor (EGF), Vas-
cular Endothelial Growth Factor (VEGF), Stromal cell-derived factor
1 (CXCL-12), Transforming Growth Factor-beta (TGF-b) and Osteo-
pontin. Mainly, EGF, the EGFR ligand, was selected for its predom-
inant contribution to the proliferation of epithelial head and neck
tumors; VEGF as inducer of angiogenesis and lymphangiogenesis;
CXCL-12 and Osteopontin because of their role in tumor invasion,
metastasization and homing of cancer cells; TGF-b for its impor-
tance in promoting tumor cell growth, cell differentiation, and
apoptosis [11–14]. The aim of our study was to explore the feasibil-
ity to detect the expression of these molecular biomarkers in WDFs
following neck dissection. In addition, we sought to evaluate their
correlation with standard clinico-pathological features of patients
undergoing radical surgery for HNSCC.2. Materials and methods
2.1. Patients’ population
For this prospective pilot study, we enrolled patients affected by
stage II-IV (according to TNM/AJCC 7th edition) HNSCC deemed
amenable to undergo radical surgery at primary tumor site en-
block with ipsilateral or bilateral elective or therapeutic neck dis-
section, with or without regional or free flap reconstruction. In
our series 17 patients (84.2%) were naïve with no history of previ-
ous treatment, 2 patients (10,5%) had a previous history of
chemoradiation therapy treatment in one case with curative intent
for an oropharyngeal carcinoma and as adjuvant therapy for an
oral cavity carcinoma (OCC) in the other; 1 patient (5,3%) was pre-
viously treated with transoral surgery for an early stage OCC. After
surgery the collected specimens were sent to the Pathology
Department of the University of Florence for a thorough histopato-
logical analysis. Neck drain tubes were placed at the end of neck
dissection procedure. WDFs of postoperative days 1 and 3 were
collected from the ipsilateral neck and immediately processed. Flu-
ids were centrifuged for 15 min at 3500 rpm, then divided in ali-
quots and stored at 70 C until analysis. The expression of EGF,
VEGF, CXCL-12, TGF-b and Osteopontin was measured using com-
mercially available enzyme linked immunosorbent assay (ELISA)
kits, with a mean minimum detectable dose of 0.089–0.740 pg/
ml for EGF, 5.0 pg/ml for VEGF, 1.0–47 pg/ml for CXCL-12, and
0.006–0.024 ng/mL for Osteopontin, respectively. Each sample
was analyzed in duplicates and then averaged for the mean value.
Quality control pools of low, normal, and high concentrations for
all parameters were included in each assay. The optical density
of each well was evaluated by the use of a microplate reader (VIC-
TOR Multilabel Plate Reader 1420 Perkin Elmer), set to a wave-
length of 450 nm. In order to correct the error caused by optical
surface imperfections, another measurement was performed with
a wavelength of 570 nm. A subtraction between the two essays
was performed. Results were expressed in pg/ml for EGF, VEGF,
CXCL-12, TGF-bwhereas the results of Osteopontin were expressed
in ng/ml. Data on WDFs analysis at postoperative days 1 and 3
were ultimately available for 19 cases. This prospective pilot studywas reviewed and approved by the University of Florence Ethics
Committee Review Board and written informed consent was
obtained from all patients.2.2. Statistical analysis
Statistical analysis was carried out using STATA 13 software
(StataCorp. 2013. Stata Statistical Software: Release 13. College
Station, TX: StataCorp LP). The significance of the observed differ-
ences between molecular assays at day 1 and day 3 was verified
with a T-Student test. The distribution of the data by dichotomous
variables was analyzed with the Fisher’s exact test. In particular
one-sided tests were computed because by observing the two-
ways tables the possibility of a one-direction relationship was
more plausible. The Wilcoxon-Mann-Whitney test was used to test
if molecular assays had a different distribution by some categorical
variables (such as surgical margins, extranodal extension etc.).
Only with regard to the tumor stage variable, the two-sided Fish-
er’s exact test was performed and the ANOVA model was used to
assess if the molecular levels (at day 1 and day 3) were differently
distributed in each group. In order to investigate if there was some
relationship between homolateral lymph node density and the five
molecular assays the Sperman’s correlation index was calculated.
The basic requirements to perform a linear regression analysis
were not satisfied but considering that this is a pilot study, we
believed that observing more in depth if a given molecular level
can vary in relation to the other molecular levels and the lymph
node density was appropriate. So a linear regression through the
backward elimination technique was performed for each of the five
molecular levels (both at day 1 and 3). A p-value of 0.05 was cho-
sen in order to establish if a variable had to remain in the model.3. Results
From November 2014 to May 2016, 19 patients affected by
stage II-IV HNSCC undergoing curatively-intended surgery were
enrolled in our study. Patients’ main clinical features are shown
in Table 1. The mean age of the cohort was 67.7 years
(SD ± 12.41; range, 51–90). According to the pathologic staging, 9
(47%) patients were classified as pT3, 6 (32%) patients as pT4a
and 4 (21%) patients as pT2, respectively. The most common pri-
mary tumor site was oral cavity (12 patients; 63.1%), followed by
oropharynx and larynx with 3 cases each (15.8% per site). Eleven
(58%) patients presented a moderately differentiated carcinoma
(G2), 4 (21%) a poorly differentiated carcinoma (G3) and 4 (21%)
a well differentiated carcinoma (G1), respectively. In the analysed
series, the most common surgical interventions were a partial glos-
sectomy, glossectomy associated to a marginal mandibulectomy,
total laryngectomy, glossectomy extended to the oropharynx, total
laryngectomy, and a segmental mandibulectomy in 5 (26,3%), 3
(15,8%), 3 (15,8%), 2 (10,5%) and 2 (10,5%) patients, respectively.
The remaining two patients underwent to an inferior maxillectomy
in one case and a total auriculectomy in the other. In 16 patients
(84.2%), the surgical resection margins were negative, whereas in
the remaining 3 patients (16%) close margins were retrieved,
defined as  3 mm. Pathologic lymph node metastases were
detected in 9 cases (47%), 5 of which (56%) presented ENE. A mean
of 67 ml of WDFs at day 1 and 42 ml at day 3 were collected per
patient, respectively. The expression of EGF and TGF- b was signif-
icantly reduced from day 1 to day 3 (mean values of 162.20 ± 86.64
to 37.39 ± 46.19 pg/ml and 4254.94 ± 1437.97 to 1026.86 ± 571.
68 pg/ml; p < 0.001 and p < 0.05, respectively). On the contrary,
the expression of CXCL-12 and Osteopontin significantly increased
from day 1 to day 3 (mean values of 15.82 ± 16.98 to 30.40 ± 11.
24 ng/ml; and 479.08 ± 66.5 to 749.68 ± 93.71 pg/ml; p < 0.001
Table 1
patients characteristics.
Tumor site Grading TNM* Margins status ENEy Perineural invasion Angio-vascular invasion Lymph-vascular invasion
1 Oral Cavity G2 T3N0 Neg Neg Neg Neg Neg
2 Oral Cavity G1 T3N2c Neg Pos Pos Pos Pos
3 Oral Cavity G2 T3N1 Neg Pos Pos Neg Neg
4 Oropharynx G2 T4aN2b Neg Neg Neg Neg Neg
5 Oropharynx G2 T3N0 Neg Neg Neg Neg Neg
6 Oropharynx G2 T2N2a Neg Pos Neg Neg Neg
7 External auricle G3 T3N0 Neg Neg Neg Neg Neg
8 Oral Cavity G3 T3N0 Neg Neg Neg Neg Neg
9 Oral Cavity G2 T3N0 Neg Neg Neg Neg Neg
10 Larynx G2 T4aN0 Neg Neg Neg Neg Neg
11 Oral Cavity G2 T4bN0 Neg Neg Neg Neg Neg
12 Oral Cavity G3 T3N1 Neg Neg Neg Neg Neg
13 Oral Cavity G1 T2N0 Neg Neg Neg Neg Neg
14 Larynx G1 T4aN1 Neg Neg Neg Neg Neg
15 Oral Cavity G3 T2N0 Neg Neg Neg Neg Neg
16 Oral Cavity G2 T4aN1 Close Pos Neg Pos Pos
17 Oral Cavity G2 T2N1 Close Pos Pos Neg Neg
18 Oral Cavity G3 T3N1 Close Neg Neg Neg Neg
19 Larynx G1 T4aN0 Neg Neg Neg Neg Neg
*TNM: 7th edition of TNM staging system.
yENE: Extranodal extension.
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showed that CXCL-2 levels significantly correlated with ENE and
close surgical margins, both at day 1 and day 3 (p = 0.001 and
0.009 for ENE, 0.001 and 0.010 for close margins, respectively).
At multivariate analysis, CXCL-2 levels in both timepoints were
the only factor which retained significance in the prediction of
close surgical margins (p = 0.028 and 0.025 for day 1 and day 3,
respectively) (Table 4). Both CXCL-2 and Ostepontin assays were
significantly correlated with ENE (p = 0.018 and 0.035 for day 1;
0.052 and 0.025 for day 3, respectively) whereas TGF- b expression
was significant at day 1 only (p = 0.038) (Table 5).4. Discussion
Currently, the lack of reliable biomarkers limits the possibility
to tailor the best therapeutic approach on an individual basis in
head and neck oncology. In this light, the identification of a panel
of predictive biomarkers is one of the biggest challenges faced by
the oncologic community. In the past few years, no conclusive evi-
dence was generated on optimal prognostic stratification of HNSCC
patients [15]. It has been reported that WDFs components can
boost tumor cells proliferation in vitro [9]: thus, their exact deter-
mination could yield potential molecular targets for adjuvant ther-
apies. In particular, Licitra et al. demonstrated that EGF-like
molecules in WDFs obtained from surgically resected HNSCC can
induce the proliferation of squamous cell carcinoma lines that
appear to be triggered by EGFR expression and activation [11].
These preliminary evidences indicated that WDFs are enriched by
several molecules (growth factors, cytokines) secreted by the host
during the wound healing process in response to surgery-relatedTable 2
wound drainage fluids-derived molecular assays.
Day 1 Day 3
Mean ± SD* Mean ± SD*
CXCL-12 516.33 ± 422.51 815.49 ± 602.17
Osteopontin 15.82 ± 11.45 30.40 ± 11.24
VEGF 1666.54 ± 956.41 2210.47 ± 1190.53
EGF 162.20 ± 86.64 37.39 ± 46.19
TGF-b 4245.94 ± 1437.97 1026.86 ± 571.68
* SD: standard deviation.tissue damage, ultimately enhancing residual tumor proliferation
[9]. Similar studies were conducted on axillary drainage fluids of
breast cancer: using reverse transcriptase (RT)-polymerase chain
reaction (PCR), Greenberg et al. [16] demonstrated that a worse
prognosis was correlated with the presence of Mucine 1 (MUC-1)
while Zhang et al. [17] correlated carcinoembryonic antigen
(CEA) and cytokeratin-19 (CK-19) with local relapse. In our study,
we decided to analyse WDFs collected on postoperative days 1
and 3 in order to assess the changes between the early and rather
bloody fluids versus late serous fluids. Based on the hypothesis that
WDFs could be representative of a neoplastic microenvironment,
in our explorative pilot feasibility study we tried to identify molec-
ular biomarkers with a potential prognostic significance. Our study
showed firstly the feasibility of testing molecular assay on postop-
erative WDFs, and secondarily highlighted how the collected data
showed a potential significant association between an increased
expression of CXCL-12 and Osteopontin with close surgical mar-
gins and ENE, whereas a decreased level of TGF- b was correlated
with ENE, respectively. Both CXCL-12 and Osteopontin are known
to be involved in tumor invasion process, metastatization and
homing of cancer cells. Müller et al. demonstrated how CXCL-12
plays a critical role in determining the metastatic destination of
tumor cells through the interaction with its tissue receptor CXCL-
4 [18]. Furthermore, a study conducted by Standard et al. showed
the contribution of Osteopontin in the process of cellular adhesion
and metastatization [19,20]. Acting through its signaling pathway,
In normal cells TGF-b is able to stop cellular proliferation by block-
ing cell cycle at G1 stage, to induce differentiation, and promote
apoptosis. In many cancer cells, the TGF-b signaling pathway is
mutated, resulting in impaired tumor proliferation. In addition,
the derangement of TGF-b pathway influences surrounding stro-
mal cells, immune cells, endothelial and smooth-muscle cells,
resulting in immunosuppression and angiogenesis, conferring
higher cancer invasiveness. Finally, TGF-b also turns off the anti-
cancer immune response converting effector T-cells into regulatory
(suppressor) T-cells [21].
Our results highlighted that increased levels of CXCL-12 and
Osteopontin, together with decreased levels of TGF-b, were corre-
lated with circumstances in which the presence of a minimal resid-
ual disease is more likely. In fact, the detection of close margins
could suggest the persistence of residual cancer cells at the pri-
mary site, while the presence of ENE could reflect the persistence
of cancer cells despite a neck dissection. Notably, the presence of
Table 3
results of linear regression with backward method for CXCL-12.
DAY 1 Coefficient CI* 95% p-value R2y
Lymph node metastasis 395 133 – 656 0.008 0.91
Angio-vascular invasion 848 1,292 – 405 0.002
Homolateral lymph node density 12795 4,055 – 21,536 0.010
ENE 779 450 – 1108 0.001
Margins 1103 1604 – 601 0.001
Intercept 218 22 – 414 0.033
DAY 3 Coefficient CI* 95% p-value R2y
ENE 757 227 – 1,287 0.009 0.59
Margins 816 1,402 – 230 0.010
Intercept 742 449 – 1034 0.000
*CI: Confidence Interval.
yR2: Coefficient of determination.
Bold numbers indicate significant values.
Table 4




Mean SDy Mean SDy p-value
CXCL-12 Day 1 121,47 ± 27,02 595,30 ± 420.21 0.028
Day 3 177,24 ± 27,44 935,16 ± 581,62 0.025
Osteopontin Day 1 17,38 ± 11,81 7,99 ± 5,29 0.173
Day 3 29,26 ± 11,95 36,45 ± 1,19 0.695
VEGF Day 1 1578,24 ± 905,63 2108,06 ± 1297,37 0.678
Day 3 2210.19 ± 1237,43 2211,99 ± 1127,80 0.911
EGF Day 1 167,65 ± 95,17 136,74 ± 1,12 0.450
Day 3 34,49 ± 41,69 51,91 ± 74,78 0.953
TGF-b Day 1 4209,92 ± 1540.51 4606,13 ± 0.00 0.752
Day 3 1069,20 ± 584,14 603,56 ± 0.00 0.527
* N: number of patients.
y SD: standard deviation
Bold numbers indicate significant values.
Table 5
correlation between extranodal extension and molecular assays.
No Yes
N*=14 N*=5
Mean SDy Mean SDy p-value
CXCL-12 Day 1 404,25 ± 276,03 807,72 ± 619,00 0.018
Day 3 626,62 ± 447,14 1344,32 ± 712,41 0.052
Osteopontin Day 1 13,03 ± 10.17 23,05 ± 12,52 0.035
Day 3 28,23 ± 12,46 36,46 ± 1,07 0.025
VEGF Day 1 1724,31 ± 1038,31 1516,34 ± 783,77 0.961
Day 3 2363,43 ± 1255,33 1782,19 ± 972,35 0.405
EGF Day 1 163,16 ± 73,76 159,90 ± 122,69 0.673
Day 3 43,26 ± 50.79 22,15 ± 30.44 0.153
TGF-b Day 1 5047,52 ± 524,81 2843,19 ± 1489,57 0.038
Day 3 1082,97 ± 353,71 928,67 ± 904,96 0.186
* N: number of patients.
y SD: standard deviation.
Bold numbers indicate significant values.
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important prognostic factors for the development of loco-
regional and distant relapses. When compared with lymph node
involvement without extracapsular spread, the identification of
ENE leads to increased rates of loco-regional failure (28.9%
vs 19.2% respectively) and of distant failure (24.4% vs 8.1%, respec-
tively) [5]. Therefore, the high-risk feature of ENE translates into
worse 5-year CSS and overall survival (OS) (48% 5-year CSS and
29% 5-year OS vs 66% and 51% rates without ENE, respectively)
[22]. We hypothesize that the presence of a minimal residual dis-
ease might influence the post-surgical microenvironment, stimu-lating overexpression of CXCL-12 and Osteopontin, and
decreasing the expression of TGF-b. These microenvironmental
features could increase the aggressiveness of residual cancer cells,
facilitating metastasis and invasion processes.
In a very preliminary way, we were able to describe a correla-
tion between molecular WDFs assays and clinico-pathological
characteristics of minimal residual disease. In the future, the
implementation of WDFs analysis on top of histopathologic exam-
ination could be a useful tool to obtain a better prognostic stratifi-
cation based on peri-operative biomarkers, allowing potentially for
a more tailored adjuvant approach. Furthermore, in line with
64 T. Gualtieri et al. / Clinical and Translational Radiation Oncology 23 (2020) 60–64previous experiences, we confirmed the feasibility of testing
molecular assays from WDFs, potentially paving the way for
further reseach in this field. Clearly, caution is advised when inter-
preting our study results, in view of its inherent limitations. The
small sample size, the relative heterogeneity of primary tumors
and disease stage and the low number of adverse pathologic
features limit the strength of our findings. Taking into account
the aforementioned considerations, no correlation was intended
to be drawn between the expression of molecular biomarkers in
WDFs and clinical outcome, therefore no inferences can be
suggested on the potential long-term prognostic impact of the
study results.
The biomolecular analysis of WDFs could represent a new
source of information on tumor microenvironment. The feasibility
of testing different assays directly from the neck surgical field in
the immediate post-operative setting was demonstrated. A poten-
tial correlation between molecular expression in drainage fluids
and the presence of histologic features associated with the persis-
tence of minimal residual disease could be also hypothesized. Fur-
ther prospective studies are warranted to clarify the usefulness of
WDFs for optimal prognostication of operated HNSCC patients.Declaration of Competing Interest
The authors declare that they have no known competing finan-
cial interests or personal relationships that could have appeared
to influence the work reported in this paper.References
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